

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSPTANXR1625

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS	1		Web Page for STN Seminar Schedule - N. America
NEWS	2	JAN 02	STN pricing information for 2008 now available
NEWS	3	JAN 16	CAS patent coverage enhanced to include exemplified prophetic substances
NEWS	4	JAN 28	USPATFULL, USPAT2, and USPATOLD enhanced with new custom IPC display formats
NEWS	5	JAN 28	MARPAT searching enhanced
NEWS	6	JAN 28	USGENE now provides USPTO sequence data within 3 days of publication
NEWS	7	JAN 28	TOXCENTER enhanced with reloaded MEDLINE segment
NEWS	8	JAN 28	MEDLINE and LMEDLINE reloaded with enhancements
NEWS	9	FEB 08	STN Express, Version 8.3, now available
NEWS	10	FEB 20	PCI now available as a replacement to DPCI
NEWS	11	FEB 25	IFIREF reloaded with enhancements
NEWS	12	FEB 25	IMSPRODUCT reloaded with enhancements
NEWS	13	FEB 29	WPINDEX/WPIDS/WPIX enhanced with ECLA and current U.S. National Patent Classification
NEWS	14	MAR 31	IFICDB, IFIPAT, and IFIUDB enhanced with new custom IPC display formats
NEWS	15	MAR 31	CAS REGISTRY enhanced with additional experimental spectra
NEWS	16	MAR 31	CA/CAPLUS and CASREACT patent number format for U.S. applications updated
NEWS	17	MAR 31	LPCI now available as a replacement to LDPCI
NEWS	18	MAR 31	EMBASE, EMBAL, and LEMBASE reloaded with enhancements
NEWS	19	APR 04	STN AnaVist, Version 1, to be discontinued
NEWS	20	APR 15	WPIDS, WPINDEX, and WPIX enhanced with new predefined hit display formats
NEWS	21	APR 28	EMBASE Controlled Term thesaurus enhanced
NEWS	22	APR 28	IMSRESEARCH reloaded with enhancements
NEWS	23	MAY 30	INPAFAMDB now available on STN for patent family searching
NEWS	24	MAY 30	DGENE, PCTGEN, and USGENE enhanced with new homology sequence search option
NEWS	25	JUN 06	EPFULL enhanced with 260,000 English abstracts
NEWS	26	JUN 06	KOREAPAT updated with 41,000 documents
NEWS	27	JUN 13	USPATFULL and USPAT2 updated with 11-character patent numbers for U.S. applications
NEWS EXPRESS	FEBRUARY 08 CURRENT WINDOWS VERSION IS V8.3, AND CURRENT DISCOVER FILE IS DATED 20 FEBRUARY 2008		
NEWS HOURS	STN Operating Hours Plus Help Desk Availability		
NEWS LOGIN	Welcome Banner and News Items		
NEWS IPC8	For general information regarding STN implementation of IPC 8		

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 15:33:07 ON 18 JUN 2008

=> file reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 15:33:25 ON 18 JUN 2008

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2008 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JUN 2008 HIGHEST RN 1028750-52-8

DICTIONARY FILE UPDATES: 17 JUN 2008 HIGHEST RN 1028750-52-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH January 9, 2008.



Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

<http://www.cas.org/support/stngen/stndoc/properties.html>

=>

Uploading C:\Program Files\Stnexp\Queries\10598944.str



```

chain nodes :
10 11 12 13 15 16 17 18 19 20 21 22
ring nodes :
1 2 3 4 5 6 7 8 9
chain bonds :
5-15 6-13 7-10 10-11 10-12 13-16 16-17 16-18 16-19 17-20 17-21 17-22
ring bonds :
1-2 1-5 2-3 3-4 3-6 4-5 4-9 6-7 7-8 8-9
exact/norm bonds :
1-2 1-5 4-5 5-15 6-13 10-11 10-12 13-16 16-18 16-19 17-20 17-21 17-22
exact bonds :
2-3 7-10 16-17
normalized bonds :
3-4 3-6 4-9 6-7 7-8 8-9
isolated ring systems :

```

containing 1 :

G1:H,Ak

Match level :

1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:Atom 7:Atom 8:Atom 9:Atom 10:CLASS
11:CLASS 12:CLASS 13:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS 19:CLASS
20:CLASS 21:CLASS 22:CLASS

L1 STRUCTURE UPLOADED

=> d l1

L1 HAS NO ANSWERS

L1 STR

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

Structure attributes must be viewed using STN Express query preparation.

=> s l1

SAMPLE SEARCH INITIATED 15:33:48 FILE 'REGISTRY'

SAMPLE SCREEN SEARCH COMPLETED - 77 TO ITERATE

100.0% PROCESSED 77 ITERATIONS

1 ANSWERS

SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**

BATCH **COMPLETE**

PROJECTED ITERATIONS: 1014 TO 2066


PROJECTED ANSWERS: 1 TO 80

L2 1 SEA SSS SAM L1

=> d

L2 ANSWER 1 OF 1 REGISTRY COPYRIGHT 2008 ACS on STN
RN 865709-24-6 REGISTRY
ED Entered STN: 20 Oct 2005
CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]- (CA INDEX NAME)
FS STEREOSEARCH
MF C19 H27 N7 O
SR CA
LC STN Files: CA, CAPLUS, CASREACT

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

1 REFERENCES IN FILE CA (1907 TO DATE)
1 REFERENCES IN FILE CAPLUS (1907 TO DATE)

=> s l1 full
FULL SEARCH INITIATED 15:34:04 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 1866 TO ITERATE

100.0% PROCESSED 1866 ITERATIONS 63 ANSWERS
SEARCH TIME: 00.00.01

L3 63 SEA SSS FUL L1

=> file caplus	SINCE FILE	TOTAL
COST IN U.S. DOLLARS	ENTRY	SESSION
FULL ESTIMATED COST	180.36	180.57

FILE 'CAPLUS' ENTERED AT 15:34:09 ON 18 JUN 2008
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jun 2008 VOL 148 ISS 25
FILE LAST UPDATED: 17 Jun 2008 (20080617/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/legal/infopolicy.html>

=> s l3 full
L4 2 L3

=> d ibib abs hitstr tot

L4 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 2005:1042248 CAPLUS

DOCUMENT NUMBER: 143:347165

TITLE: Preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors

INVENTOR(S): Coe, Diane Mary; Cook, Caroline Mary; Cooper, Anthony William James; Edlin, Christopher David; Hamblin, Julie Nicole; Johnson, Martin Redpath; Jones, Paul Spencer; Lindvall, Mika Kristian; Mitchell, Charlotte Jane; Redgrave, Alison Judith; Robinson, John Edward

PATENT ASSIGNEE(S): Glaxo Group Limited, UK

SOURCE: PCT Int. Appl., 114 pp.

CODEN: PIXXD2




DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 1

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	---	-----	-----	-----
WO 2005090353	A1	20050929	WO 2005-GB976	20050315
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1735315	A1	20061227	EP 2005-718029	20050315
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, HR, LV				
JP 2007529484	T	20071025	JP 2007-503401	20050315
US 20070167485	A1	20070719	US 2006-598944	20060915
PRIORITY APPLN. INFO.:			GB 2004-5937	A 20040316
			WO 2005-GB976	W 20050315
OTHER SOURCE(S):			CASREACT 143:347165; MARPAT 143:347165	
GI				



AB The title compds. I [R1 = Et, Pr, iso-Pr, fluoroalkyl, CH2CH2OH; R2 = H, Me, Et, etc.; NHR3 = NHCR3aR3bCR3cR3dR3e (wherein R3a = Me, Et; R3b, R3c, R3d = H, Me, Et; R3e = H, Me; with provisions); R5 = alkyl, (un)substituted cycloalkyl, (CH2)ncycloalkyl, etc.], useful as inhibitors of phosphodiesterase type IV (PDE4), and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as chronic obstructive pulmonary disease (COPD), asthma, rheumatoid arthritis or allergic rhinitis, were prepared and formulated. Thus, amidation of the acid (1S)-II (preparation given) with 2-ethylbutylamine afforded (1S)-III which showed PDE4B inhibitory activity with pIC50 of 8.1 (± about 0.5).

IT 865708-81-2P 865708-82-3P 865708-83-4P
 865708-84-5P 865708-85-6P 865708-86-7P
 865708-87-8P 865708-88-9P 865708-89-0P
 865708-90-3P 865708-91-4P 865708-92-5P
 865708-93-6P 865708-94-7P 865708-95-8P
 865708-96-9P 865708-97-0P 865708-98-1P
 865708-99-2P 865709-00-8P 865709-01-9P
 865709-02-0P 865709-03-1P 865709-04-2P
 865709-05-3P 865709-06-4P 865709-07-5P
 865709-08-6P 865709-09-7P 865709-10-0P
 865709-11-1P 865709-12-2P 865709-13-3P
 865709-14-4P 865709-15-5P 865709-16-6P
 865709-17-7P 865709-18-8P 865709-19-9P
 865709-20-2P 865709-21-3P 865709-22-4P
 865709-23-5P 865709-24-6P 865709-25-7P
 865709-26-8P 865709-27-9P 865709-28-0P
 865709-29-1P 865709-30-4P 865709-31-5P
 865709-32-6P 865709-33-7P 865709-34-8P
 865709-35-9P 865709-36-0P 865709-37-1P
 865709-38-2P


RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of pyrazolo[3,4-b]pyridines as phosphodiesterase type 4 (PDE4) inhibitors for treating inflammatory and allergic diseases)

RN 865708-81-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-dimethylpropyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-82-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-dimethylpropyl]amino]-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-83-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[(1R)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-84-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-4-[[(1R)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-85-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1R)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-86-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[4-(difluoromethoxy)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-87-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(2-methyl-4-thiazolyl)methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-88-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(5-chloro-2-pyridinyl)methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-89-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2-chloro-6-fluorophenyl)methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-90-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl-N-[1-[4-(methylsulfonyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-91-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(6-methoxy-3-pyridinyl)methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-92-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-[(methylamino)carbonyl]phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-93-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1R)-1-phenylpropyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-94-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-N-(2,2-diphenylethyl)-1-ethyl-] (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-95-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[[2-(dimethylamino)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-] (CA INDEX NAME)


Absolute stereochemistry.



RN 865708-96-9 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(4-fluorophenyl)methyl]-] (CA INDEX NAME)

Absolute stereochemistry.




RN 865708-97-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-N-(diphenylmethyl)-1-ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865708-98-1 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-[(methylamino)carbonyl]phenyl]methyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865708-99-2 CAPLUS
 CN Benzoic acid, 4-[[[4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-00-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-(4-methoxyphenyl)]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-01-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(4-hydroxyphenyl)methyl]]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865709-02-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-(trifluoromethyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-03-1 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl-N-[(4-methoxyphenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-04-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(3,4-difluorophenyl)methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-05-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,6-difluorophenyl)methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-06-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1R)-1-phenylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-07-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(2,5-difluorophenyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-08-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(3-fluorophenyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-09-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[2-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-10-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(5-chloro-2,3-dihydro-1H-inden-2-yl)-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-11-1 CAPLUS

CN Benzoic acid, 3-[[[4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-1H-pyrazolo[3,4-b]pyridin-5-yl]carbonyl]amino]methyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-12-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[2-(aminocarbonyl)phenyl]methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-13-3 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-14-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-[(methylsulfonyl)amino]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-15-5 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-16-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-17-7 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-18-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-19-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-20-2 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[2-(aminosulfonyl)ethyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-21-3 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[(1,6-dihydro-6-oxo-3-pyridinyl)methyl]-4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-22-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]-N-[2-[(methylsulfonyl)amino]ethyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 865709-23-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl]-N-(tetrahydro-2H-pyran-4-yl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-24-6 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[(1-methyl-1H-pyrazol-4-yl)methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-25-7 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-[[3-(methylsulfonyl)phenyl]methyl]]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-26-8 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[[(1S)-1,2-dimethylpropyl]amino]-1-ethyl-N-(3-pyridinylmethyl)]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-27-9 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[3-(aminocarbonyl)phenyl]methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-28-0 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl-N-[(tetrahydro-2-furanyl)methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-29-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-[[4-[(dimethylamino)sulfonyl]phenyl]methyl]-4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 865709-30-4 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[[1S]-1,2-dimethylpropyl]amino]-1-ethyl-N-(2-ethylbutyl)- (CA INDEX NAME)


Absolute stereochemistry.




RN 865709-31-5 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-(phenylmethyl)- (CA INDEX NAME)




RN 865709-32-6 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-(4-fluorophenyl)- (CA INDEX NAME)




RN 865709-33-7 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-[[4-(trifluoromethyl)phenyl]methyl]- (CA INDEX NAME)



RN 865709-34-8 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, N-(2,3-dihydro-1H-inden-2-yl)-4-[(1,1-dimethylethyl)amino]-1-ethyl- (CA INDEX NAME)




RN 865709-35-9 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 4-[(1,1-dimethylethyl)amino]-1-ethyl-N-[[4-(methylsulfonyl)phenyl]methyl]- (CA INDEX NAME)



RN 865709-36-0 CAPLUS
 CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[[(1R)-1-methylpropyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 865709-37-1 CAPLUS


CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1S)-1-methylpropyl]amino]-N-(phenylmethyl)- (CA INDEX NAME)

Absolute stereochemistry.



RN 865709-38-2 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylpropyl)amino]-N-(phenylmethyl)- (CA INDEX NAME)



REFERENCE COUNT:


5

THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 2 CAPLUS COPYRIGHT 2008 ACS on STN

ACCESSION NUMBER: 1978:190885 CAPLUS
DOCUMENT NUMBER: 88:190885
ORIGINAL REFERENCE NO.: 88:30029a,30032a
TITLE: 3,7-Dihydro- and 1,7-dihydro-4H-pyrazolo[4',3':5,6]-
pyrido[4,3-d]pyrimidin-4-ones
INVENTOR(S): Denzel, Theodor; Hoehn, Hans
PATENT ASSIGNEE(S): E. R. Squibb and Sons, Inc., USA
SOURCE: U.S., 7 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4072681	A	19780207	US 1977-773562	19770302
CA 1091667	A1	19801216	CA 1978-296875	19780215
GB 1597091	A	19810903	GB 1978-6858	19780221
DE 2809033	A1	19780907	DE 1978-2809033	19780302
JP 53109000	A	19780922	JP 1978-24360	19780302
FR 2382452	A1	19780929	FR 1978-6020	19780302
FR 2382452	B1	19801219		
PRIORITY APPLN. INFO.:			US 1977-773562	A 19770302
OTHER SOURCE(S):	MARPAT	88:190885		
GI				




AB The title compds. I and II (R = H, lower alkyl, phenyl; R1, R3, R4 = H, lower alkyl; R2 = H, lower alkyl, Ph, Ph substituted by 1 or 2 halo, lower alkyl, lower alkoxy, phenyl-lower alkyl, di(lower alkyl)amino-lower alkyl) were prepared Thus, 4-amino-1-ethylpyrazolo[3,4-b]pyridine-5-carboxylic acid was aminated with SOCl2 and NH3 followed by cyclization with HC(OEt)3 to give II (R = Et, R1-R4 = H). At 10-50 mg/kg/day I and II were antiinflammatory and at 10-15 mg/kg/day had central nervous system depressant activity.

IT 66373-12-4P

RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation and cyclization with orthoformate)

RN 66373-12-4 CAPLUS

CN 1H-Pyrazolo[3,4-b]pyridine-5-carboxamide, 1-ethyl-4-[(1-methylethyl)amino]-
(CA INDEX NAME)



=> d his

(FILE 'HOME' ENTERED AT 15:33:07 ON 18 JUN 2008)

FILE 'REGISTRY' ENTERED AT 15:33:25 ON 18 JUN 2008

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 63 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:34:09 ON 18 JUN 2008

L4 2 S L3 FULL

=> d his

(FILE 'HOME' ENTERED AT 15:33:07 ON 18 JUN 2008)

FILE 'REGISTRY' ENTERED AT 15:33:25 ON 18 JUN 2008

L1 STRUCTURE UPLOADED

L2 1 S L1

L3 63 S L1 FULL

FILE 'CAPLUS' ENTERED AT 15:34:09 ON 18 JUN 2008

L4 2 S L3 FULL

=> log y

COST IN U.S. DOLLARS

SINCE FILE

TOTAL

ENTRY

SESSION

FULL ESTIMATED COST

12.82

193.39

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)

SINCE FILE

TOTAL

ENTRY

SESSION

CA SUBSCRIBER PRICE

-1.60

-1.60

STN INTERNATIONAL LOGOFF AT 15:36:39 ON 18 JUN 2008